Mylan Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (51)

Latest Posts

About This Stock More About This Stock
Mylan (MYL) Q4 Earnings Surpass Estimates, Revenues Miss
Article By: Zacks Investment Research
Wednesday, February 28, 2018 7:00 PM EDT
Mylan N.V. reported mixed results for fourth-quarter 2017 as EpiPen sales declined. Adjusted earnings of $1.43 per share beat the Zacks Consensus Estimate of $1.41 but was down from $1.57 reported in the year-ago quarter.
In this article: MYL Also: GSK, RHHBY, TEVA
Read
Biotech Year One: A Year Of Trials Tribulations And Discovery
Article By: Kieran O'Dea
Monday, December 25, 2017 8:24 AM EDT
The biotech market is its own beast, derived from the aggregate opinions and knowledge of the mainstream thought. The market has a binary, linear, and simplistic approach to trial results ignoring the context in which each trial is conducted.
In this article: IBB, XBI, XPH, SPY, TEVA, AGN, JNJ, MYL, BMY, BIIB, PFE, MRK, INCY
Read
Bullish Inverse Head & Shoulder Breakout In Play
Article By: Chris Kimble
Monday, December 18, 2017 10:45 AM EDT
Mylan has had a rough go of it the past two years as it lost nearly 50% of its value.
In this article: MYL
Read
Pfizer/Merck KGaA Drug Fails In Study, Teva CEO Announces Changes
Article By: Arpita Dutt
Friday, December 1, 2017 8:57 AM EDT
While reports about tech giant Amazon meeting generic drugmakers made the rounds, companies like Pfizer and Teva Pharmaceutical Industries Ltd.’s were in the news with the former reporting late-stage data.
In this article: JNJ, PFE, MYL Also: BMY, GSK, TEVA, NVO
Read
Mylan (MYL) Misses On Q3 Earnings & Sales
Article By: Zacks Investment Research
Monday, November 6, 2017 11:44 AM EDT
Mylan missed on earnings. Our consensus called for EPS of $1.22, and the company reported EPS of $1.10.
In this article: MYL
Read

PARTNER HEADLINES

Latest Tweets for $MYL

No tweets yet!